Wexford Capital’s Elevance Health ELV Stock Holding History

Wexford Capital’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-559	Closed	-$254K	–	147
2022 Q3	$254K	Buy	+559	New	+$267K	0.08%	110
2021 Q1	–	Sell	-10,511	Closed	-$3.38M	–	248
2020 Q4	$3.38M	Buy	10,511 +3,502	+50%	+$1.07M	0.53%	51
2020 Q3	$1.88M	Sell	7,009 -15,312	-69%	-$4.12M	0.5%	49
2020 Q2	$5.87M	Buy	22,321 +8,321	+59%	+$2.22M	1.47%	23
2020 Q1	$3.18M	Buy	14,000 +7,140	+104%	+$1.95M	1.18%	29
2019 Q4	$2.07M	Buy	+6,860	New	+$1.89M	0.32%	67
2018 Q4	–	Sell	-9,855	Closed	-$2.7M	–	96
2018 Q3	$2.7M	Buy	+9,855	New	+$2.56M	0.17%	69
2018 Q1	–	Sell	-10,200	Closed	-$2.29M	–	121
2017 Q4	$2.29M	Buy	+10,200	New	+$2.17M	0.2%	58
2016 Q3	–	Sell	-7,508	Closed	-$986K	–	169
2016 Q2	$986K	Buy	+7,508	New	+$1.03M	0.17%	73
2014 Q4	–	Sell	-78,020	Closed	-$9.33M	–	70
2014 Q3	$9.33M	Buy	+78,020	New	+$8.95M	0.86%	18
2014 Q1	–	Sell	-72,570	Closed	-$6.71M	–	202
2013 Q4	$6.71M	Buy	+72,570	New	+$6.45M	0.57%	22

Other funds holding ELV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wexford Capital's ELV Position: Q4 2022 in Review

Wexford Capital sold out of Elevance Health (ELV) in Q4 2022, closing a stake of 559 shares — an estimated $254K sold.

Wexford Capital first reported a position in ELV in Q4 2013 and held it in 11 quarters. The position peaked at $9.33M in Q3 2014. 1,548 funds tracked by Wall St. Rank hold ELV as of Q4 2022.

Wexford Capital reported no remaining Elevance Health position as of Q4 2022 after selling out during the quarter.
Wexford Capital sold 559 Elevance Health shares in Q4 2022, an estimated $254K.
Wexford Capital first reported a position in Elevance Health in Q4 2013 and held it in 11 quarters.
Wexford Capital's Elevance Health position peaked at $9.33M in Q3 2014.
1,548 funds tracked by Wall St. Rank held Elevance Health as of Q4 2022.

Based on Wexford Capital's 13F filing for Q4 2022, filed 14 Feb 2023.